论文部分内容阅读
目的探讨替吉奥同步联合适形调强放疗对直肠癌复发患者的治疗效果。方法选取2015年6月至2016年12月间武汉大学人民医院收治的116例直肠癌复发患者,采用随机数表法分为观察组与对照组,每组58例。观察组患者采用替吉奥同步联合适形调强放射治疗,对照组患者采用适形调强放射治疗。治疗3个月后,比较两组患者的临床疗效、体力状况、生活质量及不良反应。结果治疗3个月后,观察组患者客观缓解率为46.6%,疾病控制率为91.4%,KPS功能评分为(92.23±9.61)分、QOL生活质量评分为(53.17±5.62)分,均高于对照组患者的22.8%、64.9%、(85.37±9.20)分和(43.62±5.29)分,差异均有统计学意义(均P<0.05)。两组患者不良反应发生率中,粒细胞减少症(17.2%vs 15.8%),血小板减少(15.5%vs 12.3%),乏力(22.4%vs 21.1%)和恶心、呕吐(29.3%vs 26.3%)比较,差异均无统计学意义(均P>0.05)。结论替吉奥同步联合适形调强放疗直肠癌复发患者有较好的临床疗效,改善患者体力状况和生活质量。
Objective To investigate the therapeutic effect of TIGO combined with conformal intensity-modulated radiation therapy on recurrent rectal cancer patients. Methods A total of 116 patients with rectal cancer who were admitted to Wuhan University People’s Hospital from June 2015 to December 2016 were randomly divided into observation group and control group with 58 cases in each group. Patients in the observation group were treated with TIGO in combination with conformal intensity modulated radiation therapy, and patients in the control group were treated with IMRT. After 3 months of treatment, the clinical efficacy, physical status, quality of life and adverse reactions in both groups were compared. Results After 3 months of treatment, the objective response rate was 46.6%, the disease control rate was 91.4%, the KPS functional score was (92.23 ± 9.61) and the QOL quality of life score was (53.17 ± 5.62) The difference was statistically significant (both P <0.05) in the control group, 22.8%, 64.9%, (85.37 ± 9.20) points and (43.62 ± 5.29) points respectively. In the two groups, the incidence of adverse reactions (neutropenia (17.2% vs 15.8%), thrombocytopenia (15.5% vs 12.3%), fatigue (22.4% vs 21.1%) and nausea and vomiting (29.3% vs 26.3% There was no significant difference between the two groups (all P> 0.05). Conclusions TIGO can improve the physical status and quality of life of patients with recurrent rectal cancer complicated with conformal IMRT.